GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » Gross-Profit-to-Asset %

Unipharma Co (ROCO:6621) Gross-Profit-to-Asset % : 14.29% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Unipharma Co's annualized Gross Profit for the quarter that ended in Jun. 2024 was NT$49.06 Mil. Unipharma Co's average Total Assets over the quarter that ended in Jun. 2024 was NT$343.29 Mil. Therefore, Unipharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 14.29%.


Unipharma Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Unipharma Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co Gross-Profit-to-Asset % Chart

Unipharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.91 15.90 15.54 21.92 14.95

Unipharma Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.70 25.25 17.10 12.99 14.29

Competitive Comparison of Unipharma Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Unipharma Co's Gross-Profit-to-Asset % falls into.



Unipharma Co Gross-Profit-to-Asset % Calculation

Unipharma Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=51.016/( (332.574+350.074)/ 2 )
=51.016/341.324
=14.95 %

Unipharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=49.06/( (350.074+336.51)/ 2 )
=49.06/343.292
=14.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Unipharma Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Unipharma Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines